Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ: TARS )

47.10 -0.05 (-0.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 684,570
Open 48.34
Bid (Size) 45.82 (4)
Ask (Size) 46.00 (1)
Prev. Close 47.15
Today's Range 46.91 - 49.90
52wk Range 20.08 - 57.28
Shares Outstanding 34,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Proposed $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire

Performance

YTD
-14.60%
-14.60%
1 Month
-9.00%
-9.00%
3 Month
-9.67%
-9.67%
6 Month
+48.11%
+48.11%
1 Year
+53.87%
+53.87%

More News

Read More
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Earnings Scheduled For February 25, 2025
Via Benzinga
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
Earnings Outlook For Tarsus Pharmaceuticals
Via Benzinga
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run
Via Investor's Business Daily
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.